Klaria Competitors and Similar CompaniesClear all
Takeda's competitors and similar companies include Exelixis, Halozyme Therapeutics and Puma Biotechnology.
 Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. | ||
Founding Date | Founding Date 1781 | Founding Date 1994 | Founding Date 1998 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Alameda, US HQ | Locations San Diego, US HQ | Locations Los Angeles, US HQ | |
Employees | Employees 47,4554% decrease | Employees 1,14712% decrease | Employees 373157% increase | Employees 27214% decrease |
Valuation ($) | Valuation ($) 43.7 b | Valuation ($) 8.2 b | Valuation ($) 6.4 b | Valuation ($) 136.8 m |
Financial | ||||
Revenue (est.) | Revenue (est.) ¥4.5t (FY, 2026) | Revenue (est.) $2.3b (FY, 2025) | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $228.4m (FY, 2025) |
Cost of goods | Cost of goods ¥850.5b (FY, 2026) | Cost of goods $83.7m (FY, 2025) | Cost of goods $228.8m (FY, 2025) | Cost of goods $58.2m (FY, 2025) |
Gross profit | Gross profit ¥3.7t (FY, 2026) | Gross profit $2.2b (FY, 2025) | Gross profit $1.2b (FY, 2025) | Gross profit $170.2m (FY, 2025) |
Net income | Net income ¥192b (FY, 2026) | Net income $782.6m (FY, 2025) | Net income $316.9m (FY, 2025) | Net income N/A |
Operating ⚠ | ||||
Filed Trials Products | Filed Trials Products 16 (May, 2025) | Filed Trials Products N/A | Filed Trials Products 2 (FY, 2019) | Filed Trials Products N/A |
Phase I Trials Products | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products N/A | Phase I Trials Products 10 (FY, 2020) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 17 (May, 2025) | Phase III Trials Products N/A | Phase III Trials Products 8 (FY, 2020) | Phase III Trials Products N/A |
Funding | ||||
Total funding raised | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised $ 171.9m | Total funding raised $ 172m |
For sources of this data, please see the company profile
View Company Profiles
Exelixis
HQ
Alameda, US
Employees
1,147↓ 12% decrease
Exelixis is an oncology company that develops cancer treatments.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyPuma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View company